Close Menu
Home › BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

Sep 28, 2018
|
staff reporter

NEW YORK (GenomeWeb) – The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor's susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with defective DNA repair. But not all patients respond as expected.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Cancer

  1. European Labs Continue to Validate, Implement TMB, Facing Down Cutoff Discordance Concerns

    Premium

  2. Thermo Fisher Scientific, Eli Lilly to Develop CDx for RET Inhibitor

  3. Repare Therapeutics Using CRISPR to Develop Cancer Treatments for Synthetic Lethal Targets

    Premium

  4. Roche's Tecentriq Demonstrates Survival Benefit in PD-L1 High NSCLC

  5. Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.